Folks I'm backing up the old station wagon and loading up the MNTA today. There is PR release today getting NO LOVE THAT IS HUGE FOR THIS CO..... Read it, I'll post it in a bit... Not only that they were upgraded by Rodmin & Renshaw yesterday; not only that NotableCalls had a piece out this week on the name that I put in my Where We're At thread- On NotableCalls this caught me eye Morgan Stanley is upgrading Momenta Pharma (NASDAQ:MNTA) to Overweight-V and increasing their target to $22. Firm believes the stars could be finally aligning for the FDA approval of MNTA/NVSâs M-Enox in 2008-09 as the only genericversion of SNYâs Lovenox (blood thinner), potentially leading to: 1) 40-50% share of the $1.5+ billion U.S. Lovenox market, 2) peak potential earnings of $3/sh and 3) a share price of $40+. The downside risk of a long delay or non-approval is that the stock returns to $6. Why are they upgrading now? Firm believes that the heparin (a complex sugar) contamination crisis may have given MNTA the unique opportunity to prove to the FDA its proprietary technology for characterizing complex sugars. Last weekâs Nature publication shows that MNTA worked with the FDA to identify the heparin contaminant. They view this work as a game changer, underestimated by the Street. In our opinion, the FDA is now more likely to view MNTAâs technology as sufficient to show that M-Enox is the same as Lovenox (also a complex sugar) â a key regulatory hurdle and one they feel competitors Teva and Amphastar cannot achieve. Notablecalls: This is a game-changing upgrade for this stock. Morgan Stanley has been neg on MNTA for quite some time (UW rating) and now they are saying the stock could do $35+ under bullish scenario. The NC crew missed the fact that a news release further down shows MNTA announcing a presentation at.... of course Morgan. It's always hard to figure out the order of these things is the presentation set and then as luck would have it herceptin gets tainted or does the Co have a story to tell now... the fact that the co worked with the FDA in the emergency lends major creed to their case in my view. Perhaps sometime between today and the presentation Wed this could be bought for a nice hold. Big price target. Ok we have new FDA news going into a speech today and a stk not reacting @$15.... opportunities like this is why I keep my nose to the grindstone every day. I bought this name lightly yesterday in anticipation of the analyst meeting at Morgan as well now we have an upgrade this news and another presentation on May FIVE..... This has some BIG possibilities a large super drug to be sure and a co that now seems to be on the same page with the FDA... this is a 1 year DOUBLE. Stoney PT. ~ $30.